Comparison of the Hyperkalemic Effects of Erythropoietin and U-74389G
Published on: 2019-08-14
Aim: This study estimated the effects on serum potassium (K) levels, after the treatment with either of these 2 drugs: the cytokine erythropoietin (Epo) and the pure antioxidant lazaroid (L) drug U-74389G. The estimation was based on the outcomes of 2 preliminary studies. Each preliminary study calculated a certain hyperkalemia, after the respective drug administration in an experiment of induced rat ischemia reperfusion (IR).
Materials and methods: The 2 main interexperimental endpoints at which the serum K levels were measured were the 60th reperfusion min (for A, C and E groups) and the 120th reperfusion min (for B, D and F groups). Specifically, the groups A and B were placebo, groups C and D were processed by Epo; whereas groups E and F by L administration.
Results: The first preliminary study was that of Epo. It showed a non-significant hyperkalemic effect by 0.18%+2.22% (p-value=0.9338). The other preliminary study, that of U-74389G, presented a non-significant hyperkalemic effect by 2.07%+3.03% (p-value=0.4853). Both studies were co-estimated since they came from a common experimental setting. The result of the co-estimation was that L is 11.4937-fold [11.42513 - 11.56268] more hyperkalemic than Epo (p-value=0.0000).
Conclusions: The anti-oxidant capacities of U-74389G ascribe 11.4937-fold more hyperkalemic effects than Epo (p-value=0.0000).